New prognostic factors and developing therapy of cutaneous melanoma

Annals of Medicine

Volumn 35, Issue 2, 2003, Pages 66-78

  Vihinen, Pia P ^a,b   Pyrhönen, Seppo O ^a,b   Kähäri, Veli Matti ^a,c  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c UNIVERSITY OF TURKU   (Finland)

Author keywords

Angiogenesis; Cell adhesion; Gene therapy; Integrin; Melanoma; Metalloproteinase; Prognosis; Staging; Vaccine

Indexed keywords

ANGIOGENESIS INHIBITOR; CHEMOKINE; HERMES ANTIGEN; INTEGRIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; MELAN A; MELANOMA ASSOCIATED PROTEIN; MELANOMA INHIBITOR PROTEIN; METALLOPROTEINASE; MONOPHENOL MONOOXYGENASE; PROTEIN; PROTEIN S100B; PROTEINASE; TUMOR CELL VACCINE; TUMOR MARKER; UNCLASSIFIED DRUG;

ANGIOGENESIS; BIODIVERSITY; CANCER CLASSIFICATION; CANCER STAGING; CANCER THERAPY; DISEASE MARKER; DNA FINGERPRINTING; DNA MICROARRAY; GENE EXPRESSION; GENE THERAPY; HUMAN; MELANOMA; MOLECULAR BIOLOGY; MOLECULAR GENETICS; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; REVIEW; ULCEROGENESIS; VACCINATION;

ANTIGENS, CD44; ANTIGENS, NEOPLASM; CANCER VACCINES; CHEMOKINES; EXTRACELLULAR MATRIX PROTEINS; GENE THERAPY; HUMANS; IMMUNOHISTOCHEMISTRY; INTEGRINS; MATRIX METALLOPROTEINASES; MELANOMA; MONOPHENOL MONOOXYGENASE; NEOPLASM PROTEINS; NEOPLASM STAGING; NERVE GROWTH FACTORS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; S100 PROTEINS; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0038102611     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.1080/07853890310009980     Document Type: Review

References (119)

1. Balch CM, Soong S-J, Shaw HM, Urist MM, McCarthy WH. An analysis of prognostic factors in 8500 patients with cutaneous melanoma. In: Balch CM, Houghton AN, Milton GW, Sober AJ, Soong S-J, eds. Cutaneous melanoma. Philadelphia, PA: JB Lippincott Company; 1992: 165-87.
2. Fitzpatrick TB, Milton GW, Balch CM, Shaw HM, McCarthy WH, Sober AJ. Clinical characterstics. In: Balch CM, Houghton AN, Milton GW, Sober AJ, Soong S-J, eds. Cutaneous melanoma. Philadelphia, PA: JB Lippincott Company; 1992: 223-33.
3. Clark WJ, Elder DE, Guerry D, Epstein MN, Greene MH, Van HM. A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Hum Pathol 1984; 15: 1147-65.
4. Ortonne J-P. Photobiology and genetics of malignant melanoma. Br J Dermatol 2002; 146: S11-6.
5. Diepgen TL, Mahler V. The epidemiology of skin cancer. Br J Dermatol 2002; 146: S1-6.
6. Balch CM, Buzaid AC, Soong S-J, Atkins MB, Cascinelli N, Coit DG, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19: 3635-48.
7. Legha SS, Ring S, Eton O, Bedikian A, Buzaid AC, Plager C, et al. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol 1998; 16: 1752-9.
8. Gray RJ, Pockaj BA, Kirkwood JM. An update on adjuvant interferon for melanoma. Cancer Control 2002; 9: 16-21.
9. Eggermont AM. The role interferon-alpha in malignant melanoma remains to be defined. Eur J Cancer 2001; 37: 2147-53.
10. Bachter D, Michl C, Buchels H, Vogt H, Balda BR. The predictive value of the sentinel lymph node in malignant melanomas. Recent Results Cancer Res 2001; 158: 129-36.
11. Balch CM, Soong S-J, Gershenwald JE, Thompson JF, Reitgen DS, Cascinelli N, et al. Prognostic factors analysis of 17, 600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001; 19: 3622-34.
12. Retsas S, Henry K, Mohammed MQ, MacRae K. Prognostic factors of cutaneous melanoma and a new staging system proposed by the American Joint Committee on Cancer (AJCC). validation in a cohort of 1284 patients. Eur J Cancer 2002; 38: 511-6.
13. Essner R, Kuo CT, Wang H, Wen DR, Turner RR, Nguyen T, et al. Prognostic implications of p53 overexpression in cutaneous melanoma from sun-exposed and non-exposed sites. Cancer 1998; 82: 309-16.
14. Vogt T, Zipperer KH, Vogt A, Holzel D, Landthaler M, Stolz W. p53-protein and Ki-67-antigen expression are both reliable biomarkers of prognosis in thick stage I nodular melanomas of the skin. Histopathology 1997; 30: 57-63.
15. Weiss J, Heine M, Korner B, Pilch H, Jung EG. Expression of p53 protein in malignant melanoma: clinicopathological and prognostic implications. Br J Dermatol 1995; 133: 23-31.
16. Straume O, Akslen LA. Alterations and prognostic significance of p16 and p53 protein expression in subgroups of cutaneous melanoma. Int J Cancer 1997; 74: 535-9.
17. Talve LA, Collan YU, Ekfors TO. Nuclear morphometry, immunohistochemical staining with Ki-67 antibody and mitotic index in the assessment of proliferative activity and prognosis of primary malignant melanomas of the skin. J Cutan Pathol 1996; 23: 335-433.
18. Sparrow LE, Eldon MJ, English DR, Heenan PJ. p16 and p21waf1 protein expression in melanocytic tumors by immunohistochemistry. Am J Dermatopathol 1998; 20: 255-61.
19. Karjalainen JM, Eskelinen MJ, Kellokoski JK, Reinikainen M, Alhava EM, Kosma VM. p21(Waf1/Cip1) expression in stage I cutaneous malignant melanoma: its relationship with p53, cell proliferation and survival. Br J Cancer 1999; 79: 895-902.
20. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-54.
21. Heino J. The collagen receptor integrins have distinct ligand recognition and signaling functions. Matrix Biol 2000; 19: 319-23.
22. Santala P, Heino J. Regulation of integrin-type cell adhesion receptors by cytokines. J Biol Chem 1991; 266: 23505-9.
23. Santala P, Larjava H, Nissinen L, Riikonen T, Määttä A, Heino J. Suppressed collagen gene expression and induction of α2β1 integrin-type collagen receptor in tumorigenic derivatives of human osteogenic sarcoma (HOS) cell line. J Biol Chem 1994; 269: 1276-83.
24. Petitclerc E, Stromblad S, von Schalscha TL, Mitjans F, Piulats J, Montgomery AM, et al. Integrin αvβ3 promotes M21 melanoma growth in human skin by regulating tumor cell survival. Cancer Res 1999; 59: 2724-30.
25. Brooks PC, Stromblad S, Sanders LC, von Schalscha TL, Aimes RT, Stetler-Stevenson WG, et al. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell 1996; 85: 683-93.
26. Kageshita T, Hamby CV, Hirai S, Kimura T, Ono T, Ferrone S. αvβ3 expression on blood vessels and melanoma cells in primary lesions: differential association with tumor progression and clinical prognosis. Cancer Immunol Immunother 2000; 49: 314-8.
27. Ruegg C, Yilmaz A, Bieler G, Bamat J, Chaubert P, Lejeune FJ. Evidence for the involvement of endothelial cell integrin αvβ3 in the distruption of the tumor vasculature induced by TNF and IFN-gamma. Nat Med 1998; 4: 408-14.
28. Vihinen P, Nikkola J, Vlaykova T, Hahka-Kemppinen M, Talve L, Heino J, et al. Prognostic value of β1 integrin expression in metastatic melanoma. Melanoma Res 2000; 10: 243-51.
29. Gilhar A, Ullmann Y, Kalish RS, Berkutski T, Azizi E, Bank I. Favorable melanoma prognosis associated with the expression of the tumor necrosis factor receptor and the α1β1 integrin: a preliminary report. Melanoma Res 1997; 7: 486-95.
30. Hieken TJ, Farolan M, Ronan SG, Shilkaitis A, Wild L, Das Gupta TK. β3 integrin expression in melanoma predicts subsequent metastasis. J Surg Res 1996; 63: 169-73.
31. Hieken TJ, Ronan SG, Farolan M, Shilkaitis AL, Das Gupta TK. Molecular prognostic markers in intermediate-thickness cutaneous melanoma. Cancer 1999; 85: 375-82.
32. Schadendorf D, Heidel J, Gawlik C, Surer L, Czarnetski BM. Association with clinical outcome of expression of VLA-4 in primary cutaneous malignant melanoma as well as P-selectin and E-selectin on intratumoral vessels. J Natl Cancer Inst 1995; 87: 366-71.
33. Westermarck J, Kähäri V-M. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 1999; 13: 781-92.
34. Berking C, Takemoto R, Schaider H, Showe L, Satyamoorthy K, Robbins P, et al. Transforming growth factor beta-1 increases survival of human melanoma through stroma remodeling. Cancer Res 2001; 61: 8306-16.
35. Kähäri V-M, Saarialho-Kere U. Matrix metalloproteinases and their inhibitors in tumour growth and invasion. Ann Med 1999; 31: 34-45.
36. Ahonen M, Baker AH, Kähäri V-M. Adenovirus-mediated gene delivery of tissue inhibitor of metalloproteinases-3 inhibits invasion and induces apoptosis in melanoma cells. Cancer Res 1998; 58: 2310-5.
37. Ahonen M, Ala-aho R, Baker AH, George SJ, Grénman R, Saarialho-Kere U, et al. Antitumor activity and by-stander effect of adenovirally delivered tissue inhibitor of metalloproteinases-3. Mol Ther 2002; 5: 705-15.
38. Matoska J, Wahlstrom T, Vaheri A, Bizik J, Grofova M. Tumor-associated β2-macroglobulin in human melanomas. Int J Cancer 1988; 41: 359-63.
39. Vihinen P, Kähäri V-M. Matrix metalloproteinases in cancer: Prognostic markers and therapeutic targets. Int J Cancer 2002; 99: 157-66.
40. Väisänen A, Kallioinen M, Taskinen PJ, Turpeenniemi-Hujanen T. Prognostic value of MMP-2 immunoreactive protein (72 kD type IV collagenase) in primary skin melanoma. J Pathol 1998; 186: 51-8.
41. Nikkola J, Vihinen P, Vlaykova T, Hahka-Kemppinen M, Kähäri V-M, Pyrhönen S. High collagenase-1 expression correlates to favorable chemoimmunotherapy response in human metastatic melanoma. Melanoma Res 2001; 11: 157-66.
42. Nikkola J, Vihinen P, Vlaykova T, Hahka-Kemppinen M, Kähäri V-M, Pyrhönen S. High expression levels of collagenase-1 and stromelysin-1 correlate with shorter disease-free survival in human metastatic melanoma. Int J Cancer 2002; 97: 432-8.
43. Simon JC, Heider KH, Dietrich A, Wuttig C, Schopf E, Adolf GR, et al. Expression of CD44 isoforms in human skin cancer. Eur J Cancer 1996; 32A: 1394-400.
44. Karjalainen JM, Tammi RH, Tammi MI, Eskelinen MJ, Agren UM, Parkkinen JJ, et al. Reduced level os CD44 and hyaluronan associated with unfavorable prognosis in clinical stage I cutaneous melanoma. Am J Pathol 2000; 157: 957-65.
45. Ranuncolo SM, Ladeda V, Gorostidy S, Morandi A, Varela M, Lastiri J, et al. Expression of CD44s and CD44 splice variants in human melanoma. Oncol Rep 2002; 9: 51-6.
46. Schaider H, Soyer HP, Heider KH, Hofmann-Wellenhof R, Zatloukal K, Smolle J, et al. CD44 and variants in melanocytic skin neoplasms. J Cutan Pathol 1998; 25: 199-203.
47. Schaider H, Rech-Weichselbraun I, Richtig E, Seidl H, Soyer HP, Smolle J, et al. Circulating adhesion molecules as prognostic factors for cutaneous melanoma. J Am Acad Dermatol 1997; 36: 209-13.
48. Dietrich A, tanczos E, Vanscheidt W, Schopf E, Simon JC. High CD44 surface expression on primary tumors of malignant melanoma correlates with increased metastatic risk and reduced survival. Eur J Cancer 1997; 33: 926-30.
49. Curry BJ, Myers K, Hersey B. Polymerase chain reaction detection of melanoma cells in the circulation: relation to clinical stage, surgical treatment, and recurrence from melanoma. J Clin Oncol 1998; 16: 1760-9.
50. Quereux G, Denis M, Khammari A, Lustenberger P, Dreno B. Prognostic value of tyrosinase reverse-transcriptase polymerase chain reaction in metastatic melanoma. Dermatology 2001; 203: 221-5.
51. Bostick PJ, Morton DL, Turner RR, Huynh KT, Wang HJ, Elashoff R, et al. Prognostic significance of occult metastases detected by sentinel lymphadenectomy and reverse transcriptase-polymerase chain reaction in early-stage melanoma patients. J Clin Oncol 1999; 17: 3238-44.
52. Hoon DS, Kuo CT, Wascher RA, Fournier P, Wang HJ, O'Day SJ. Molecular detection of metastatic melanoma cells in cerebrospinal fluid in melanoma patients. J Invest Dermatol 2001; 117: 375-8.
53. Curry BJ, Myers K, Hersey P. MART-1 is expressed less frequently on circulating malanoma cells in patients who develop distant compared with locoregional metastases. J Clin Oncol 1999; 17: 2562-71.
54. Bosserhoff AK, Kaufmann M, Kaluza B, Bartke I, Zirngibl H, Hein R, et al. Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. Cancer Res 1997; 57: 3149-53.
55. Juergensen A, Holzapfel U, Hein R, Stolz W, Buettner R, Bosserhoff A. Comparison of two prognostic markers for malignant melanoma: MIA ans S100 beta. Tumour Biol 2001; 22: 54-8.
56. Martenson ED, Hansson LO, Nilsson B, von Schoultz E, Mansson Brahme E, Ringborg U, et al. Serum S-100b protein as a prognostic marker in malignant cutaneous melanoma. J Clin Oncol 2001; 19: 824-31.
57. Meral R, Duranyildiz D, Tas F, Camlica H, Yasasever V, Kurul S, et al. Prognostic significance of melanoma inhibiting activity levels in malignant melanoma. Melanoma Res 2001; 11: 627-32.
58. Stahlecker J, Gauger A, Bosserhoff A, Buttner R, Ring J, Hein R. MIA as a reliable tumor marker in the serum of patients with malignant melanoma. Anticancer Res 2000; 20: 5041-4.
59. Djukanovic D, Hofmann U, Sucker A, Rittgen W, Schadendorf D. Comparison of S100 protein and MIA protein as serum marker for malignant melanoma. Anticancer Res 2000; 20: 2203-7.
60. Payne AS, Cornelius LA. The role of chemokines in melanoma tumor growth and metastasis. J Invest Dermatol 2002; 118: 915-22.
61. Müller A, Homey B, Soto H, Ge N, Caton D, Buchanan ME, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410: 50-6.
62. Ugurel S, Rappl G, Tilgen W, Reinhold U. Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol 2001; 19: 577-83.
63. Huang S, Mills L, Mian B, Tellez C, McCarty M, Yang XD, et al. Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. Am J Pathol 2002; 161: 125-34.
64. Bystryn JC, Albrecht J, Reynolds SR, Rivas MC, Oratz R, Shapiro RL, et al. Decrease in circulating tumor cells as an early marker of therapy effectiveness. Recent Results Cancer Res 2001; 158: 204-7.
65. Aoudjit F, Vuori K. Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells. Oncogene 2001; 20: 4995-5004.
66. Hasan NM, Adams GE, Joiner MC, Marshall JF, Hart IR. Hypoxia facilitates tumor cell detachment by reducing expression of surface adhesion molecules and adhesion to extracellular matrices without loss of cell viability. Br J Cancer 1998; 77: 1799-805.
67. Castel S, Pagan R, Garcia R, Casaroli-Marano RP, Reina M, Mitjans F, et al. αv integrin antagonists induce the dissembly of focal contacts in melanoma cells. Eur J Cell Biol 2000; 79: 502-12.
68. Mitjans F, Meyer T, Fittschen C, Goodman S, Jonczyk A, Marshall JF, et al. In vivo therapy of malignant melanoma by means of antagonists of αv integrins. Int J Cancer 2000; 87: 716-23.
69. Kumar CC, Malkowski M, Yin Z, Tanghetti E, Yarenko B, Nechuta T, et al. Inhibition of angiogenesis and tumor growth by SCH221153, a dual αvβ3 and αvβ5 integrin receptor antagonist. Cancer Res 2001; 61: 2232-8.
70. Buerkle MA, Pahernik SA, Sutter A, Jonczyk A, Messmer K, Dellian M. Inhibition of the alpha-nu integrins with a cyclic RGD peptide impairs angiogenesis, growth and metastasis of solid tumours in vivo. Br J Cancer 2002; 86: 788-95.
71. Teronen O, Heikkilä P, Konttinen YT, Laitinen M, Salo T, Hanemaaijer R, et al. MMP inhibition and downregulation by Bisphosphanates. Ann NY Acad Sci 1999; 878: 453-65.
72. Seftor RE, Seftor EA, De Larco JE, Kleiner DE, Leferson J, Stetler-Stevenson W, et al. Chemically modified tetracyclines inhibit human melanoma cell invasion and metastasis. Clin Exp Metastasis 1998; 16: 217-25.
73. Lee HM, Golub LM, Cao J, Teronen O, Laitinen M, Salo T, et al. CMT-3, a non-antimicrobial tetracycline (TC), inhibits MT1-MMP activity: relevance to cancer. Curr Med Chem 2001; 8: 257-60.
74. Hidalgo M, Eckhardt SG. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst 2001; 93: 178-93.
75. Collier MA, Gonzalez R, Smylie M, O'Day S, Anderson C, Bedikian AY, et al. Phase II, parallel-design study of the matrix metalloproteinase (MMP) inhibitor prinomastat in combination with weekly paclitaxel (T) in patients (PTS) with metastatic melanoma. Proc ASCO 2002 (abstract #1828).
76. Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol 1992; 3: 65-71.
77. National Cancer Institute. Angiogenesis inhibitors in clinical trials. Expanded trial information. (a) Thalidomide Protocol NCI-G00-1786; (b) Thalidomide Protocol SWOG-S0026; (c) Anti-VEGF Antibody Protocol NCI-2669. http://www.cancer.gov/clinicaltrials/developments/anti-angiotable-info (checked 25 11 02).
78. Danson S, Arance A, Lorigan P, Clamp A, Hodgetts J, Lomax L, et al. A randomized study of temozolomide (TMZ) alone, with interferon (TMZ-IFN) or with thalidomide (TMZ-THAL) in metastatic malignant melanoma (MMM). Proc ASCO 2002 (abstract #1369).
79. Foda HD, Zucker S. Matrix metalloproteinases in cancer invasion, metastasis and angiogenesis. Drug Discov Today 2001; 6: 478-82.
80. Wylie S, MacDonald IC, Varghese HJ, Schmidt EE, Morris VL, Groom AC, et al. The matrix metalloproteinase inhibitor batimastat inhibits angiogenesis in liver metastases of B16F1 melanoma cells. Clin Exp Metastasis 1999; 17: 111-7.
81. Shalinsky DR, Brekken J, Zou H, McDermott CD, Forsyth P, Edwards D, et al. Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. Ann NY Acad Sci 1999; 878: 236-70.
82. Foon KA, Sen G, Hutchins L, Kashala OL, Baral R, Banerjee M, et al. Antibody responses in melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2. Clin Cancer Res 1998; 4: 1117-24.
83. Toso JF, Gill VJ, Hwu P, Marincola FM, Restifo NP, Schwartzentruber DJ, et al. Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol 2002; 20: 142-52.
84. Livingston PO, Adluri S, Helling F, Yao TJ, Kensil CR, Newman MJ, et al. Phase I trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet heamocyanin conjugate vaccine in patients with malignant melanoma. Vaccine 1994; 12: 1275-80.
85. Kirkwood JM, Ibrahim JG, Sosman JA, Sondak VK, Agarwala SS, Ernstoff MS, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001; 19: 2370-80.
86. Schreiber S, Kampgen E, Wagner E, Pirkhammer D, Trcka J, Korschan H, et al. Immunotherapy of metastatic malignant melanoma by a vaccine consisting of autologous interleukin 2-transfected cancer cells: outcome of a phase I study. Hum Gen Ther 1999; 10: 983-93.
87. Hsueh EC, Nathanson L, Foshag LJ, Essner R, Nizze JA, Stern SL, et al. Active spesific immunotherapy with polyvalent melanoma cell vaccine for patients with in-transit melanoma metastases. Cancer 1999; 85: 2160-9.
88. Tsioulias GJ, Gupta RK, Tisman G, Hsueh EC, Essner R, Wanek LA, et al. Serum TA90 antigen-antibody complex as a surrogate marker for the efficacy of a polyvalent allogeneic whole-vell vaccine (CancerVax) in melanoma. Ann Surg Oncol 2001; 8: 198-203.
89. Wallack MK, Sivanandham M, Balch CM, Urist MM, Bland KI, Murray D, et al. Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial. J Am Coll Surg 1998; 187: 69-77.
90. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998; 4: 321-7.
91. Wang F, Bade E, Kuniyoshi C, Spears L, Jeffery G, Marty V, et al. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma. Clin Cancer Res 1999; 5: 2756-65.
92. Brinckerhoff LH, Thompson LW, Slingluff CLJ. Melanoma vaccines. Curr Opin Oncol 2000; 12: 163-73.
93. Rochlitz CF. Gene therapy of cancer. Swiss Med Wkly 2001; 131: 4-9.
94. Nemunaitis J, Fong T, Burrows F, Bruce J, Peters G, Ognoskie N, et al. Phase I trial of interferon gamma retroviral vector administered intratumorally with multiple courses in patients with metastatic melanoma. Hum Gene Ther 1999; 10: 1289-98.
95. Fujii S, Huang S, Fong TC, Ando D, Burrows F, Jolly DJ, et al. Induction of melanoma-associated antigen systemic immunity upon intratumoral delivery of interferon-gamma retroviral vector in melanoma patients. Cancer Gene Ther 2000; 7: 1220-30.
96. Klatzmann D, Cherin P, Bensimon G, Boyer O, Coutellier A, Charlotte F, et al. A phase I/II dose-escalation study of herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for metastatic melanoma. Study Group on Gene Therapy of Metastatic Melanoma. Hum Gene Ther 1998; 9: 2585-94.
97. Stopeck AT, Jones A, Hersh EM, Thompson JA, Finucane DM, Gutheil JC, et al. Phase II study of direct intralesional gene transfer of allovectin-7, an HLA-B7/beta2-microglobulin DNA-liposome complex, in patients with metastatic melanoma. Clin Cancer Res 2001; 7: 2285-91.
98. Sotomayor MG, Hu H, Antonia S, Sotomayor EM, Pardoll DM. Advances in gene therapy for malignant melanoma. Cancer Control 2002; 9: 39-48.
99. Siders WM, Halloran PJ, Fenton RG. Melanoma-specific cytotoxicity induced by a tyrosinase promoter-enhancer/herpes simplex virus thymidine kinase adenovirus. Cancer Gene Ther 1998; 5: 281-91.
100. Ojeifo JO, Lee HR, Rezza P, Su N, Zwiebel JA. Endothelial cell-based systemic gene therapy of metastatic melanoma. Cancer Gene Ther 2001; 8: 636-48.
101. Sosman JA, Unger JM, Liu PY, Kempf R, Flaherty LE, Thompson J, et al. HLA-A2 and/or HLA-C3 expression defines a subset of T3N0 melanoma patients with improved overall survival from Melacine vaccine: an updated analysis of SWOG 9035. Proc ASCO 2002 (abstract #1359).
102. Bittner M, Meltzer P, Chen Y, Jiang Y, Seftor E, Hendrix M, et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 2000; 406: 536-40.
103. von Eggeling F, Davies H, Lomas L, Fiedler W, Junker K, Claussen U, et al. Tissue-specific microdissection coupled with ProteinChip array technologies: applications in cancer research. Biotechniques 2000; 29: 1066-70.
104. Natali PG, Niconyra MR, Cavaliere R, Giannarelli D, Bigotti A. Tumor progression in human malignant melanoma is associated with changes in α6β1 laminin receptor. Int J Cancer 1991; 49: 168-72.
105. Kageshita T, Hamby CV, Hirai S, Kimura T, Ono T, Ferrone S. Differential clinical significance of αvβ3 expression in primary lesions of acral lentigious melanoma and of other melanoma histiotypes. Int J Cancer 2000; 89: 153-9.
106. Hoffman UB, Westphal JR, Zendman AJ, Becker JC, Ruiter DJ, van Muijen GNP. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type matrix metalloproteinase 1 (MT1-MMP) correlate with melanoma progression. J Pathol 2000; 191: 245-56.
107. Van der Oord JJ, Paemen L, Opdenakker G, de Wolf-Peeters C. Expression of gelatinase B and the extracellular matrix metalloproteinase inducer EMMPRIN in benign and malignant pigment cell lesions of the skin. Am J Pathol 1997; 151: 665-70.
108. Klein CE, Steinmayer T, Kaufmann D, Weber L, Bröcker E-B. Identification of a melanoma progression antigen as an integrin VLA-2. J Invest Dermatol 1991; 96: 281-4.
109. Sturm RA, Satyamoorthy K, Meier F, Gardiner BB, Smit DJ, Vaidya B, et al. Osteonectin/SPARC induction by ectopic β3 integrin in human radial growth phase primary melanoma cells. Cancer Res 2002; 62: 226-32.
110. Airola K, Karonen T, Vaalamo M, Lehti K, Lohi J, Kariniemi A-L, et al. Expression of collagenases-1 and -3 and their inhibitors TIMP-1 and -3 correlates with the level of invasion in malignant melanomas. Br J Cancer 1999; 80: 733-43.
111. Väisänen A, Kallioinen M, Taskinen PJ, Turpeenniemi-Hujanen T. Prognostic value of MMP-2 immunoreactive protein (72 kD type IV collagenase) in primary skin melanoma. J Pathol 1998; 186: 51-8.
112. Ruiz P, Dunun D, Sonnenberg A, Imhof BA. Suppression of mouse melanoma metastasis by EA-1, a monoclonal antibody specific for α6 integrins. Cell Adhes Commun 1993; 1: 67-81.
113. Lee P, Wang F, Kuniyoshi J, Rubio V, Stuges T, Groshen S, et al. Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma. J Clin Oncol 2001; 19: 3836-47.
114. Batliwalla FM, Bateman BA, Serrano D, Murray D, Macphail S, Maino VC, et al. A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell response. Mol Med 1998; 4:783-94.
115. DiFronzo LA, Gupta RK, Essner R, Foshag LJ, O'Day SJ, Wanek LA, et al. Enhanced humoral immune response correlates with improved disease-free and overall survival in American Joint Committee on Cancer stage II melanoma patients receiving adjuvant polyvalent vaccine. J Clin Oncol 2002; 20: 3242-8.
116. Nabel, GJ, Nabel EG, Yang ZY, Fox BA, Plautz GE, Gao Z, et al. Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci USA 1993; 90: 11307-11.
117. Nabel GJ, Gordon D, Bishop DK, Nickoloff BJ, Yang ZY, Aruga A, et al. Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes. Proc Natl Acad Sci USA 1996; 93: 15388-93.
118. Mastrangelo MJ, Maquire HC, Jr, Eisenlohr LC, Laughlin CE, Monken CE, McCue PA, et al. Intratumoral recombinant GM-CSF-encoding virus as gene therapv in patients with cutaneous melanoma. Cancer Gene Ther 1999; 6: 409-22.
119. Galanis E, Hersh EM, Stopeck AT, Gonzales R, Burch P, Spier C, et al. Immunotherapy of advanced malignancy by direct gene transfer of an interleukin-2 DNA/DMRIE/DOPE lipid complex: phase I/II experience. J Clin Oncol 1999; 17: 3313-23.